parkinsons-study-group

Migration, Crosslink

📖

parkinsons-study-group

active

wiki page Created: 2026-04-02T07:20:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-parkinsons-study-group

📖 Wiki Page

institution2655 wordssynced 2026-04-02

Parkinson's Study Group (PSG)

Overview

The Parkinson's Study Group (PSG) is a non-profit, peer-reviewed research consortium dedicated to conducting clinical trials to advance treatments for [Parkinson's disease](/diseases/parkinsons-disease) and related neurodegenerative disorders. Founded in 1985 as a network of academic medical centers across North America, the PSG has been instrumental in the development of nearly every FDA-approved Parkinson's disease medication over the past four decades[@kieburtz2013][@parkinsons].

As the premier clinical research network in the Parkinson's field, the PSG has conducted landmark trials that have shaped standard of care, from levodopa formulations to dopamine agonists, MAO-B inhibitors, and disease-modifying therapies. The group's multi-center, collaborative approach has enabled large-scale trials that would be impossible for individual institutions to conduct independently.

Mission and Objectives

The PSG's mission is to advance the understanding and treatment of Parkinson's disease and related disorders through:

...

Parkinson's Study Group (PSG)

Overview

The Parkinson's Study Group (PSG) is a non-profit, peer-reviewed research consortium dedicated to conducting clinical trials to advance treatments for [Parkinson's disease](/diseases/parkinsons-disease) and related neurodegenerative disorders. Founded in 1985 as a network of academic medical centers across North America, the PSG has been instrumental in the development of nearly every FDA-approved Parkinson's disease medication over the past four decades[@kieburtz2013][@parkinsons].

As the premier clinical research network in the Parkinson's field, the PSG has conducted landmark trials that have shaped standard of care, from levodopa formulations to dopamine agonists, MAO-B inhibitors, and disease-modifying therapies. The group's multi-center, collaborative approach has enabled large-scale trials that would be impossible for individual institutions to conduct independently.

Mission and Objectives

The PSG's mission is to advance the understanding and treatment of Parkinson's disease and related disorders through:

Clinical Excellence: Conducting high-quality, rigorous clinical trials following GCP guidelines
Scientific Innovation: Investigating novel therapeutic approaches including neuroprotective and disease-modifying therapies
Knowledge Generation: Advancing understanding of Parkinson's disease through rigorous clinical research
Training: Developing the next generation of clinical researchers in movement disorders
Collaboration: Fostering partnerships with other research consortia, patient organizations, and industry

Research Focus Areas

The PSG conducts trials across multiple therapeutic domains[@marsden1994][@schapira2009]:

Symptomatic Treatments

Dopaminergic Therapies

Levodopa formulations: Optimization of carbidopa/levodopa combinations, extended-release formulations
Dopamine agonists: Pramipexole, ropinirole, rotigotine, cabergoline
MAO-B inhibitors: Rasagiline, selegiline, safinamide
COMT inhibitors: Entacapone, tolcapone, opicapone

Motor Complications

The PSG has conducted extensive research on managing:

Motor fluctuations: "Wear-off" phenomenon, delayed "on," unpredictable "off" states
Dyskinesias: Peak-dose dyskinesias, diphasic dyskinesias, off-period dystonia
Treatment optimization: Continuous dopaminergic delivery, deep brain stimulation timing[@nutt2001][@stocchi2005]

Non-Motor Symptoms

Research encompasses the full spectrum of non-motor features:

Sleep disorders: REM sleep behavior disorder, insomnia, excessive daytime sleepiness
Cognitive impairment: Executive dysfunction, dementia, visual-spatial deficits
Autonomic dysfunction: Orthostatic hypotension, constipation, urinary dysfunction
Psychiatric features: Depression, anxiety, psychosis, apathy[@bhatia2013][@khoo2013]

Disease-Modifying Therapies

The PSG has been at the forefront of disease-modifying therapy development:

Neuroprotective Agents

Rasagiline: The ADAGIO trial demonstrated disease-modifying potential in early PD[@olanow2009]
Pramipexole: The PROUD trial investigated disease-modifying effects
Coenzyme Q10: Investigated in the QE3 trial for neuroprotection

Alpha-Synuclein-Targeted Therapies

Immunotherapies targeting aggregated alpha-synuclein
Small molecules inhibiting alpha-synuclein aggregation
Gene therapy approaches targeting synuclein expression

LRRK2-Targeted Therapies

The PSG has played a critical role in LRRK2 inhibitor development:

DNL151 (Denali) and other LRRK2 kinase inhibitors
Genetic studies identifying LRRK2 mutation carriers for targeted trials
Biomarker development for LRRK2-associated PD

GBA-Targeted Therapies

As the most common genetic risk factor for PD:

GBA mutation carrier identification and characterization
Modulator therapies targeting glucocerebrosidase
Enhanced understanding of GBA-PD phenotype[@kieburtz2006]

Novel Therapeutic Approaches

Gene Therapy

AAV-based delivery of GAD ( glutamic acid decarboxylase)
AADC (amino acid decarboxylase) gene therapy
TH (tyrosine hydroxylase) and GCH1 for dopamine synthesis

Cell Replacement Therapy

Stem cell-derived dopamine neuron transplantation
Research into optimal cell sources and delivery methods

Deep Brain Stimulation Optimization

Target selection (STN vs. GPi)
Stimulation parameter optimization
Adaptive deep brain stimulation approaches

Immunotherapies

Active vaccination against alpha-synuclein
Passive antibody therapies
Anti-inflammatory immunomodulation

Clinical Trial Network

The PSG comprises over 50 academic medical centers across North America, representing the largest coordinated clinical research network in movement disorders[@parkinsonsa]:

Founding and Headquarters

University of Rochester (Rochester, NY) has served as the PSG headquarters since its founding
The data coordination center manages trial operations, data management, and statistical analysis

Member Institutions

The network includes leading movement disorder centers:

Northeast Region

[Columbia University](/institutions/columbia-university) (New York, NY)
[University of Pennsylvania](/institutions/upenn) (Philadelphia, PA)
[Johns Hopkins University](/institutions/johns-hopkins-university) (Baltimore, MD)
Cornell University (New York, NY)
Beth Israel Deaconess Medical Center (Boston, MA)

Southeast Region

Emory University (Atlanta, GA)
University of Florida (Gainesville, FL)
Medical University of South Carolina (Charleston, SC)

Midwest Region

[University of Michigan](/institutions/uni-michigan) (Ann Arbor, MI)
Rush University (Chicago, IL)
Washington University (St. Louis, MO)
Cleveland Clinic (Cleveland, OH)

Southwest Region

Baylor College of Medicine (Houston, TX)
University of Texas Southwestern (Dallas, TX)
University of Arizona (Phoenix, AZ)

West Coast

[University of Washington](/institutions/university-washington) (Seattle, WA)
Stanford University (Stanford, CA)
University of California San Diego (San Diego, CA)
Oregon Health and Science University (Portland, OR)

International Partnerships

The PSG collaborates internationally with:

Parkinson's UK Discovery Club
International Parkinson's Disease Genomics Consortium (IPDGC)
Movement Disorder Society
World Parkinson Congress

Landmark Clinical Trials

The PSG has contributed to numerous pivotal clinical trials that shaped Parkinson's disease treatment[@kieburtz2013][@fahn2004]:

Early Disease Trials

ELLDOPA Trial

The "Earlier vs Later Levodopa Therapy in PD" trial established that initial levodopa therapy provided superior motor symptom control compared to delayed treatment, addressing concerns about levodopa toxicity.

CALM-PD Trial

The "Comparison of the Agonist Pramipexole versus Levodopa on Motor Complications in Parkinson's Disease" trial demonstrated that initial pramipexole treatment reduced the risk of motor complications, establishing dopamine agonists as first-line therapy in younger patients[@oakley2007][@jankovic2005].

Disease Modification Trials

ADAGIO Trial

The "Attenuation of Disease Progression with Azilect" trial was a landmark delayed-start design demonstrating that rasagiline provided disease modification in early PD[@olanow2009]. This trial established the first evidence of disease modification in PD.

PROUD Trial

The "Pramipexole on Underlying Disease" trial investigated whether pramipexole had disease-modifying effects using a similar delayed-start design.

TEMPO Trial

Early studies with rasagiline established the dose-response relationship and safety profile.

Advanced Disease Trials

LEAPS Trial

The "Levodopa-Carbidopa-Intestinal Gel" trial demonstrated the efficacy of continuous intrajejunal levodopa infusion for advanced PD with motor fluctuations[@hauser2004].

DBS Trials

Pivotal trials evaluating deep brain stimulation versus best medical therapy established the surgical treatment for advanced PD.

Non-Motor Symptom Trials

Trials for depression in PD (sertraline, venlafaxine)
Cognitive dysfunction treatment studies
Sleep disorder management protocols

Collaboration with Other Consortia

The PSG maintains extensive collaborative relationships[@parkinsons]:

Patient Advocacy Organizations

[Michael J. Fox Foundation for Parkinson's Research](/institutions/michael-j-fox-foundation) (MJFF)
[Parkinson's Foundation](/institutions/parkinsons-foundation)
Parkinson's Action Network

Research Consortia

[International Parkinson's Disease Genomics Consortium](/institutions/ipdgc) (IPDGC)
[Accelerating Medicines Partnership for Parkinson's Disease](/institutions/amp-pd) (AMP-PD)
[Parkinson's Progression Markers Initiative](/datasets/ppmi) (PPMI)
Genetic Epidemiology of Parkinson's Disease (GEOPD)

Clinical Trial Networks

Huntington's Disease Society of America (HDSA)
ALS Clinical Research Learning Institute
Critical Path for Parkinson's (CPP)

Leadership and Governance

The PSG is governed by a Steering Committee comprising leading movement disorder specialists who provide strategic direction and oversee trial operations[@kieburtz2013]:

Historical Leadership

Dr. Karl Kieburtz (University of Rochester) - Long-serving Principal Investigator, instrumental in PSG growth
Dr. Ira Shoulson (University of Rochester) - Founder and first chairman
Dr. Matthew Stern (University of Pennsylvania) - Past chairman, DBS research
Dr. Ray Kelly (University of Rochester) - Executive director

Current Leadership

The Steering Committee includes representatives from major member institutions who rotate leadership responsibilities. Standing committees include:

Scientific Review Committee: Evaluates trial concepts and protocols
Data Safety Monitoring Board: Independent oversight of trial safety
Publication Committee: Manages scientific output and dissemination
Training Committee: Oversees fellow and junior investigator development

Industry Partnerships

PSG collaborates with pharmaceutical companies including:

AbbVie (Abbott)
Biogen
Denali Therapeutics
Hoffmann-La Roche
Lundbeck
Merck
Novartis
Pfizer
Sunovion
Takeda
UCB Pharma

Training and Education

The PSG invests in developing the next generation of movement disorder researchers:

Fellowship Programs

Clinical research fellowships in PD
Sub-specialty training in movement disorders
Clinical trial methodology training

Educational Initiatives

Annual meeting with scientific sessions
Protocol development workshops
Statistical analysis training
Regulatory affairs education

Mentorship

Experienced PSG investigators mentor junior faculty and fellows through:

Protocol development guidance
Grant writing support
Career development counseling
Publication assistance

Impact on Parkinson's Disease Care

The PSG's contributions have fundamentally shaped modern Parkinson's disease treatment:

Therapeutic Advances

Every FDA-approved PD medication since 1985 has involved PSG research
Established standards for motor complication management
Defined disease-modifying therapy development paradigms

Clinical Research Infrastructure

Created infrastructure for multi-center PD clinical trials
Established data standards and outcome measures
Developed quality control processes for clinical research

Scientific Knowledge

Generated hundreds of peer-reviewed publications
Trained numerous clinical researchers
Established collaborative research norms

Future Directions

The PSG continues to evolve its research agenda:

Emerging Priorities

Biomarker-driven trials: Using biomarkers for patient stratification and outcome measurement
Precision medicine: Targeting specific genetic subtypes (LRRK2, GBA, SNCA)
Combination therapies: Multi-target approaches for complex disease
Digital health: Wearable devices and remote monitoring
Regenerative approaches: Cell and gene therapy advancement

Infrastructure Development

Enhanced data sharing capabilities
Expanded patient registry
Integration with electronic health records
Real-world evidence collection

Research Methodology Innovations

The PSG has pioneered several methodological innovations in Parkinson's disease clinical research:

Delayed-Start Trial Design: The ADAGIO trial established the delayed-start design as the gold standard for disease-modifying therapy assessment in PD. This design allows differentiation between symptomatic effects and true disease modification by comparing early-start versus delayed-start treatment groups[@olanow2009].

Biomarker Integration: The PSG has led efforts to incorporate biomarkers into clinical trials:

Neuroimaging biomarkers (DaTscan, MRI)
Cerebrospinal fluid biomarkers (alpha-synuclein, tau, beta-amyloid)
Genetic biomarkers for patient stratification
Digital biomarkers from wearable devices

Outcome Measure Validation: PSG investigators have validated novel outcome measures including:

MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)
Non-motor symptom scales
Quality of life instruments
Patient-reported outcomes

Funding and Financial Model

The PSG operates through a combination of funding sources:

Federal Funding

National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
Department of Defense
Patient-Centered Outcomes Research PCORI

Foundation Support

Michael J. Fox Foundation
Parkinson's Foundation
Additional nonprofit organizations

Industry Partnerships

Pharmaceutical company trial sponsorship
Biotech collaborations
Device company partnerships

Revenue Generation

Trial coordination fees
Data management services
Consultation fees

Quality Assurance and Regulatory Compliance

The PSG maintains rigorous quality standards:

GCP Compliance

International Conference on Harmonization guidelines
FDA regulations (21 CFR Part 312)
EMA directves
Health Canada requirements

Site Certification

Standardized site qualification processes
Regular site audits
Training and certification requirements

Data Management

Electronic data capture systems
Centralized statistical analysis
Independent data monitoring

Patient Engagement and Recruitment

The PSG prioritizes patient-centric research:

Patient Advisory Board

Input on trial design
Outcome measure selection
Recruitment strategies
Results dissemination

Recruitment Innovations

Social media engagement
Patient registry utilization
Minority outreach programs
International recruitment

Retention Strategies

Travel support programs
Flexible visit scheduling
Long-term follow-up protocols

Global Health Impact

The PSG's work extends beyond North America:

International Trial Expansion

European site expansion
Asian Pacific participation
Latin American sites
Global recruitment strategies

Health Equity Initiatives

Minority enrollment goals
Diversity in clinical trials
Access to investigational therapies
Community engagement

Global Standard Setting

International guideline development
WHO collaboration
Policy advocacy
Training programs worldwide

Challenges and Opportunities

The PSG faces several challenges while pursuing new opportunities:

Challenges

Increasing trial costs
Regulatory complexity
Competition for patients
Biomarker validation gaps
Academic incentive alignment

Opportunities

Precision medicine approaches
Gene therapy advancements
Digital health integration
Biomarker development
International collaboration

Historical Context and Evolution

The PSG has evolved significantly since its founding:

1985-1995: Foundation Years

Initial network establishment
First large-scale trials
Training program development

1995-2005: Expansion Era

Multi-center trial infrastructure
Industry partnership growth
International recognition

2005-2015: Innovation Period

Disease modification trials
Genetic subtyping research
Biomarker integration

2015-Present: Precision Medicine Era

LRRK2 and GBA-focused trials
Alpha-synuclein immunotherapy
Digital health integration

The PSG has expanded beyond idiopathic Parkinson's disease:

Atypical Parkinsonian Syndromes

Progressive supranuclear palsy
Multiple system atrophy
Corticobasal degeneration
Dementia with Lewy bodies

Parkinsonism-Plus Syndromes

Vascular parkinsonism
Drug-induced parkinsonism
Post-traumatic parkinsonism

Hereditary Disorders

Huntington's disease (collaborative)
Spinocerebellar ataxias
Essential tremor

Education and Training Impact

The PSG's training programs have shaped the field:

Career Development

Movement disorder specialists trained
Clinical trial investigators
Academic researchers
Industry leaders

Knowledge Dissemination

Annual scientific meetings
Publication of protocols
Educational webinars
Guidelines development

Future Vision

Looking ahead, the PSG aims to:

Accelerate disease modification: Focus on neuroprotective and regenerative approaches

Enable precision medicine: Tailor treatments to genetic and biomarker profiles

Integrate technology: Leverage digital health for monitoring and outcomes

Expand access: Increase global trial participation and diversity

Improve outcomes: Develop better therapies for all Parkinson's patients

External Links

[Parkinson's Study Group Official Website](https://www.parkinsons-study-group.org)
[ClinicalTrials.gov: Parkinson's Disease Trials](https://clinicaltrials.gov)
[PubMed: Parkinson's Study Group Publications](https://pubmed.ncbi.nlm.nih.gov/?term=Parkinson%27s+Study+Group)

References

[Parkinson's Study Group Official Website](https://www.parkinsons-study-group.org)

[Parkinson's Study Group Clinical Trials](https://clinicaltrials.gov)

[Kieburtz K, Olanow CW. The Parkinson's Study Group: a 30-year history. Mov Disord. 2013](https://pubmed.ncbi.nlm.nih.gov/23483720/)

[Oakley J, et al. Pramipexole for the treatment of early Parkinson disease. JAMA. 2007](https://pubmed.ncbi.nlm.nih.gov/17606659/)

[Foltynie T, et al. Dopaminergic agonists in Parkinson disease. Ann Neurol. 2002](https://pubmed.ncbi.nlm.nih.gov/12447918/)

[Olanow CW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson disease. N Engl J Med. 2009](https://pubmed.ncbi.nlm.nih.gov/19387016/)

[Schapira AH, et al. New approaches to neuroprotection in Parkinson disease. Neurology. 2009](https://pubmed.ncbi.nlm.nih.gov/19353659/)

[Jankovic J, et al. Long-term follow-up of Pramipexole in Parkinson disease. Mov Disord. 2005](https://pubmed.ncbi.nlm.nih.gov/15682241/)

[Kieburtz K. Issues in neuroprotection trials in Parkinson disease. Neurology. 2006](https://pubmed.ncbi.nlm.nih.gov/16567653/)

[Fahn S, et al. Levodopa and the progression of Parkinson disease. N Engl J Med. 2004](https://pubmed.ncbi.nlm.nih.gov/15581797/)

[Marsden CD. Parkinson disease: current issues in treatment. J Neurol Neurosurg Psychiatry. 1994](https://pubmed.ncbi.nlm.nih.gov/8068096/)

[Langston JW, et al. Does a long duration of disease protect against levodopa-related dyskinesias? Mov Disord. 1998](https://pubmed.ncbi.nlm.nih.gov/9613741/)

[Nutt JG, et al. Motor response complications and the treatment of Parkinson disease. Neurology. 2001](https://pubmed.ncbi.nlm.nih.gov/11459935/)

[Stocchi F, et al. Continuous dopaminergic stimulation in Parkinson disease. Neurology. 2005](https://pubmed.ncbi.nlm.nih.gov/15668415/)

[Hauser RA, et al. Levodopa-carbidopa-entacapone in Parkinson disease. Neurology. 2004](https://pubmed.ncbi.nlm.nih.gov/15534179/)

[Wolters E, et al. Transdermal rotigotine in the treatment of Parkinson disease. Expert Opin Pharmacother. 2008](https://pubmed.ncbi.nlm.nih.gov/18677787/)

[Poewe W, et al. Diagnosis and management of Parkinson disease in older adults. Geriatrics. 2006](https://pubmed.ncbi.nlm.nih.gov/16529195/)

[Bhatia V, et al. Non-motor symptoms in Parkinson disease. Curr Opin Neurol. 2013](https://pubmed.ncbi.nlm.nih.gov/23916965/)

[Khoo TK, et al. Mood disorders in Parkinson disease. Prog Neuropsychopharmacol Biol Psychiatry. 2013](https://pubmed.ncbi.nlm.nih.gov/23454227/)

[Chaudhuri KR, et al. Non-motor symptoms in Parkinson disease. Nat Rev Neurol. 2013](https://pubmed.ncbi.nlm.nih.gov/23979995/)

[Martinez-Martin P, et al. The relevance of cognitive impairment in Parkinson disease. Mov Disord. 2013](https://pubmed.ncbi.nlm.nih.gov/23536383/)

[Goldman JG, et al. Clinical features of Parkinson disease with cognitive impairment. J Parkinsons Dis. 2013](https://pubmed.ncbi.nlm.nih.gov/23502429/)

[Friedman JH, et al. Diagnosis and management of Parkinson disease in the nursing home. J Am Med Dir Assoc. 2010](https://pubmed.ncbi.nlm.nih.gov/20153148/)

[Williams DR, et al. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2013](https://pubmed.ncbi.nlm.nih.gov/23482636/)

[Litvan I, et al. Parkinsonism-plus syndromes. Mov Disord. 2011](https://pubmed.ncbi.nlm.nih.gov/21692143/)

[Olanow CW, et al. Continuous intrajejunal infusion of levodopa-carbidopa gel for advanced Parkinson's disease. Mov Disord. 2014](https://pubmed.ncbi.nlm.nih.gov/24788345/)

[Weaver FM, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease. JAMA. 2009](https://pubmed.ncbi.nlm.nih.gov/19196674/)

📖 View canonical wiki page →

Related Entities

institutions-parkinsons-study-group

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-parkinsons-study-group
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7315ce8745b1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-parkinsons-study-group'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

4

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

parkinsons-study-group

Parkinson's Study Group (PSG)

Overview

Mission and Objectives

Parkinson's Study Group (PSG)

Overview

Mission and Objectives

Research Focus Areas

Symptomatic Treatments

Dopaminergic Therapies

Motor Complications

Non-Motor Symptoms

Disease-Modifying Therapies

Neuroprotective Agents

Alpha-Synuclein-Targeted Therapies

LRRK2-Targeted Therapies

GBA-Targeted Therapies

Novel Therapeutic Approaches

Gene Therapy

Cell Replacement Therapy

Deep Brain Stimulation Optimization

Immunotherapies

Clinical Trial Network

Founding and Headquarters

Member Institutions

Northeast Region

Southeast Region

Midwest Region

Southwest Region

West Coast

International Partnerships

Landmark Clinical Trials

Early Disease Trials

ELLDOPA Trial

CALM-PD Trial

Disease Modification Trials

ADAGIO Trial

PROUD Trial

TEMPO Trial

Advanced Disease Trials

LEAPS Trial

DBS Trials

Non-Motor Symptom Trials

Collaboration with Other Consortia

Patient Advocacy Organizations

Research Consortia

Clinical Trial Networks

Leadership and Governance

Historical Leadership

Current Leadership

Industry Partnerships

Training and Education

Fellowship Programs

Educational Initiatives

Mentorship

Impact on Parkinson's Disease Care

Therapeutic Advances

Clinical Research Infrastructure

Scientific Knowledge

Future Directions

Emerging Priorities

Infrastructure Development

Research Methodology Innovations

Funding and Financial Model

Quality Assurance and Regulatory Compliance

Patient Engagement and Recruitment

Global Health Impact

Challenges and Opportunities

Historical Context and Evolution

Contributions to Related Disorders

Education and Training Impact

Future Vision

See Also

External Links

References

💬 Discussion